<DOC>
	<DOCNO>NCT02748330</DOCNO>
	<brief_summary>This single-center , randomize , open-label , active-controlled , parallel-group study investigate platelet inhibition Ticagrelor versus Clopidogrel acetylsalicylic acid ( ASA ) background therapy approximate 40 patient stable coronary artery disease ( SCAD ) type 2 diabetes mellitus ( DM ) recent successful elective percutaneous coronary intervention ( PCI ) evaluation P2Y12 reaction unit ( PRU ) VerifyNow P2Y12 assay 2-4 hour first study drug dose treatment day 15±2 .</brief_summary>
	<brief_title>Platelet Inhibition Ticagrelor Versus Clopidogrel Type 2 Diabetic Patients After Elective Percutaneous Coronary Intervention</brief_title>
	<detailed_description>The study consist screening period , 15±2 day treatment period , 7 day follow-up period . The screening period 7 day . Once patient sign informed consent , eligibility patient determine screening , laboratory assessment take ( Visit 1 ) . During treatment period , patient participate study randomize receive either Ticagrelor ASA , Clopidogrel ASA 15±2 day . The final dose study medication administer study site morning day 15±2 . Study visit begin ( Visit 2 ) end treatment period ( Visit 4 ) allow assessment platelet function . At 7±1 day Visit 2 , telephone visit ( Visit 3 ) carry collection information concomitant medication , adverse event ( include vascular event ) , safety end point event . After platelet function test Visit 4 finish , patient group discontinue study medication ( end treatment , EOT ) . A follow-up period begin 1 day Visit 4 continue 7 day . During follow-up period , patient Ticagrelor group take Clopidogrel 600 mg load dose first day , follow Clopidogrel 75 mg maintenance dose second day 6 day ; patient Clopidogrel group continue take Clopidogrel 75 mg maintenance dose 7 day . Both adverse event ( include vascular event ) safety end point event collect safety visit ( Visit 5 ) , occur 7 day Visit 4 . The study last approximately 4 week per patient . After informed consent sign patient , adverse event ( include vascular event ) , safety end point event concomitant medication record visit .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1 . Provision write informed consent ( patient appropriate designee accord local regulation ) prior study specific procedure . 2 . Aged 18 year old , male female . 3 . Documented stable coronary artery disease ( CAD ) fulfil follow : History stable angina pectoris angiographic evidence CAD ( diameter stenosis ≥ 50 % ) major , i.e. , leave main , leave anterior descending , leave circumflex , right coronary artery . History previous myocardial infarction ( MI ) History coronary revascularization , i.e. , percutaneous coronary intervention ( PCI ) coronary artery bypass graft ( CABG ) , include elective PCI index hospitalization 4 . Documented history type 2 diabetes mellitus . 5 . At least 24 hour within 14 day angiographically successful elective PCI without complication . Postprocedural residual diameter stenosis treat lesion &lt; 20 % patient stent implantation &lt; 50 % balloon angioplasty Postprocedural thrombolysis myocardial infarction ( TIMI ) grade 3 flow treat vessel 6 . Negative cardiac troponin test index elective PCI . 7 . Taking Clopidogrel 75 mg daily dose least 7 day take Clopidogrel 75 mg daily dose less 7 day 300 600 mg Clopidogrel load dose PCI . 8 . Taking acetylsalicylic acid ( ASA ) 100 mg daily treatment least 7 day take ASA 100 mg daily dose less 7 day 300 mg ASA load dose PCI . 9 . Females childbearing potential ( i.e. , female postmenopausal surgically sterile ) must : negative urine blood pregnancy test enrolment prior randomization ; currently use hormonal contraceptive agree continue use addition use doublebarrier local contraception ( i.e. , intrauterine device plus spermicidal condom male partner ) screening study completion . 1 . Patients acute coronary syndrome ( ACS ) within 12 month screen . 2 . Occurrence myocardial infarction ( MI ) relate index elective PCI ( type 4a MI ) myocardial infarction relate stent thrombosis ( type 4b MI ) accord Third Universal Definition Myocardial Infarction . 3 . Use parenteral antithrombotic agent , e.g. , glycoprotein IIb/IIIa inhibitor ( GPIs ) , bivalirudin , unfractionated heparin , enoxaparin fondaparinux within 24 hour screen . 4 . Use oral antithrombotic agent , exception Clopidogrel ASA , within 30 day screen . 5 . Any indication ( e.g. , atrial fibrillation , prosthetic heart valve , venous thromboembolism , ventricular thrombosis , et al ) antithrombotic treatment ASA 100 mg daily , Clopidogrel Ticagrelor study period . 6 . Concomitant therapy moderate strong cytochrome P450 ( CYP ) 3A inhibitor , CYP 3A substrate narrow therapeutic index , strong CYP 3A inducer study period . 7 . Concomitant therapy moderate strong CYP 2C19 inhibitor , CYP 2C19 substrate narrow therapeutic index , strong CYP 2C19 inducer study period . 8 . Increased bleeding risk include : recent ( within 30 day screen ) gastrointestinal ( GI ) bleeding ; history intracranial , intraocular , retroperitoneal , spinal bleeding ; recent ( within 30 day screen ) major trauma major surgery ; sustain uncontrolled hypertension ( systolic blood pressure [ SBP ] &gt; 180 mmHg diastolic blood pressure [ DBP ] &gt; 100 mmHg ) ; history hemorrhagic disorder increase risk bleeding , e.g. , haemophilia , von Willebrand 's disease ; inability discontinue require concomitant therapy nonselective nonsteroidal antiinflammatory drug ( NSAIDs ) screening ; platelet count less 100,000/mm3 hemoglobin &lt; 10 g/dL . 9 . Contraindication reason ASA , Clopidogrel , Ticagrelor administer ( e.g. , hypersensitivity , active bleeding [ include active pathological bleeding ] , bleed tendency [ coagulation defect ] , moderate severe hepatic impairment , risk bradycardia , chronic obstructive pulmonary disease , chronic active asthma , hyperuricemia , gout , etc. ) . 10 . History intolerance ASA , Clopidogrel Ticagrelor . 11 . Patients schedule CABG study period . 12 . Patient require dialysis creatinine clearance ( Clcr ) &lt; 30 mL/min calculate CockcroftGault equation : Clcr = ( 140 Age ) × WT / ( 72 × Scr ) ( × 0.85 female ) , WT weight kg , Scr serum creatinine mg/dL . 13 . Any acute chronic unstable condition past 30 day condition , opinion investigator , may either put patient risk influence result study ( e.g. , active cancer , risk noncompliance , risk lose followup ) . 14 . Participation another investigational drug device study within 30 day screen . 15 . Involvement plan conduct study ( applies investigator , contract research organization staff , study site staff ) . 16 . History drug addiction alcohol abuse previous 2 year . 17 . Recent ( within 30 day screen ) blood donation . 18 . Known pregnancy , breastfeeding , intend become pregnant study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>